Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMSV2WZ)

Drug Name
Chlorotrianisene Drug Info
Synonyms
Anisene; Chloortrianisestrol; Chlorestrolo; Chlorotrianisenum; Chlorotrianisestrol; Chlorotrianisine; Chlorotrianizen; Chlorotrisin; Chlortrianisen; Chlortrianisene; Chlortrianisenum; Chlortrianisestrol; Chlortrianisoestrolum; Chlortrianizen; Clorestrolo; Clorotrianisene; Clorotrianiseno; Clorotrisin; Hormonisene; Khlortrianizen; Merbentul; Metace; Rianil; TACE; Triagen; Trianisestrol; Chlorotrianisene [Nonsteroidal oestrogens]; Clorotrianisene [DCIT]; Chlorotrianisene (INN); Chlorotrianisene [BAN:INN]; Chlorotrianisene [INN:BAN]; Chlorotrianisenum [INN-Latin]; Clorotrianiseno [INN-Spanish]; TACE (TN); Tace (pharmaceutical); Tace-fn; Chlorotris(p-methoxyphenyl)ethylene; Tri-p-anisylchloroethylene; Tris(p-methoxyphenyl)chloroethylene; 1,1',1''-(1-Chloro-1-ethenyl-2-ylidene)-tris(4-methoxybenzene); 1,1',1''-(2-chloroethene-1,1,2-triyl)tris(4-methoxybenzene); 1,1',1''-(2-chloroethene-1,1,2-triyl)tris[4-(methyloxy)benzene]; 1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
11289
ChEBI ID
CHEMBL3641
CAS Number
CAS 569-57-3
TTD Drug ID
D0X0KJ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Complement and coagulation cascades 2.24 0.00e+0 76/85 (89.41%) TFPI;CLU;CD59;...
Retinol metabolism 2.19 0.00e+0 41/68 (60.29%) ADH1B;UGT2B15;ADH1C;...
Tryptophan metabolism 2.13 4.14e-3 35/42 (83.33%) TDO2;MAOA;CYP1A2;...
Drug metabolism 2.04 9.32e-3 78/151 (51.66%) ADH1B;UGT2B15;ADH1C;...
Pyruvate metabolism 2.03 7.46e-3 41/47 (87.23%) PCK1;ADH1B;ADH1C;...
Phagosome 2.00 1.04e-2 118/152 (77.63%) TLR4;THBS2;CYBB;...
Systemic lupus erythematosus 2.00 8.88e-3 45/135 (33.33%) C1QA;C6;CD86;...
Steroid hormone biosynthesis 1.97 9.32e-3 43/61 (70.49%) UGT2B15;CYP1A2;UGT2B28;...
Metabolism of xenobiotics by cytochrome P450 1.95 9.67e-3 49/77 (63.64%) ADH1B;UGT2B15;ADH1C;...
Fatty acid degradation 1.91 1.37e-2 40/43 (93.02%) ADH1B;ADH1C;ACSL1;...
Toll-like receptor signaling pathway 1.89 1.24e-2 94/104 (90.38%) TLR4;CXCL11;CXCL9;...
Ascorbate and aldarate metabolism 1.87 1.55e-2 15/30 (50%) UGT2B15;UGT2B28;UGT2B17;...
Staphylococcus aureus infection 1.87 1.53e-2 72/95 (75.79%) FPR3;CFB;C1QA;...
Caffeine metabolism 1.84 1.95e-2 5/6 (83.33%) CYP1A2;NAT2;NAT1;...
Citrate cycle (TCA cycle) 1.82 2.32e-2 30/30 (100%) PCK1;DLD;ACLY;...
Intestinal immune network for IgA production 1.81 2.64e-2 38/48 (79.17%) CXCL12;TNFRSF17;CD86;...
Nitrogen metabolism 1.80 2.71e-2 16/17 (94.12%) GLUL;CA12;CPS1;...
Malaria 1.80 2.62e-2 44/50 (88%) TLR4;THBS2;CD36;...
Bile secretion 1.77 3.21e-2 68/90 (75.56%) PRKACB;GNAS;UGT2B15;...
PPAR signaling pathway 1.77 3.05e-2 66/74 (89.19%) PCK1;FABP4;HMGCS2;...
Viral protein interaction with cytokine and cytokine re... 1.76 3.08e-2 84/100 (84%) CXCL14;CXCL12;CXCL11;...
Pertussis 1.76 2.94e-2 64/76 (84.21%) TLR4;IRF8;LY96;...
Inflammatory bowel disease 1.75 3.08e-2 58/65 (89.23%) TLR4;MAF;IFNGR1;...
Primary bile acid biosynthesis 1.74 3.06e-2 15/17 (88.24%) AMACR;CYP39A1;SCP2;...
Neutrophil extracellular trap formation 1.70 4.13e-2 101/189 (53.44%) TLR4;CYBB;FPR3;...
Renin secretion 1.69 4.54e-2 61/69 (88.41%) PRKACB;GNAS;GUCY1A1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM - 20uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 20uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM - 20uM 6H, 24H